Galectin-1 (Gal-1) helps tumor escape, and also modulates the formation of new blood vessels that promote tumor cell proliferation and metastasis. In addition, prevents the onset of autoimmune (multiple sclerosis) and chronic inflammation diseases (atherosclerosis).
Candidate product: Human anti-Gal-1 monoclonal antibody: specifically blocks the activity of Gal-1 secreted by the tumour, thereby increasing the anti-tumor immune response and simultaneously reducing the formation of blood vessels (neovascularization).
Candidate product: Gal-1 variant: enhanced structural stability and biological activity in adverse inflammatory microenvironments (acidic and oxidative, e.g. neurodegeneration in sclerosis multiple)
Gal-1 is highly expressed in tumors and its high level correlates with a worse prognosis. Gal-1 contributes to two fundamental phenomena for tumor growth and dissemination: A) evasion of the immune system, preventing it from exerting its anti-tumoural action, and B) generation of new blood vessels that provide oxygen and nutrients to the growing tumour.
Candidate product: Human anti-Gal-1 monoclonal antibody: specifically blocks the activity of Gal-1 secreted by the tumour, thereby increasing the anti-tumor immune response and simultaneously reducing the formation of blood vessels (neovascularization).
Gal-1 suppresses autoimmune and inflammatory responses, and tunes the activity of different cell populations restoring homeostasis.
Candidate product: Gal-1 variant: enhanced structural stability and biological activity in adverse inflammatory microenvironments (acidic and oxidative, e.g. neurodegeneration in sclerosis multiple)
DiscoveryPreclinicalAnti-Gal-1 mAb
Colorectal Cancer
DiscoveryPreclinicalGal-1 variant
Multiple Sclerosis
Atherosclerosis
Discovery
Preclinical
IND Enabling
Phase I
Discovery
Preclinical
IND Enabling
Phase I